CFTR potentiators: not an open and shut case.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25101884.
- Also identified by DOI 10.1126/scitranslmed.3009674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Insights into the positive and negative effects of drugs to treat cystic fibrosis (CF) patients with a common mutation raise questions about how we discover and translate CF therapeutics (Veit et al. and Cholon et al., this issue).
Medical subject headings
- Cystic Fibrosis Transmembrane Conductance Regulator